Additionally, multiplexed magnetic nanoparticle-antibody conjugates combining MUC16, B2M, and APOA1 achieved high sensitivity (94%) and specificity (98%) in distinguishing early-stage ovarian cancer patients from healthy individuals (Pal et al., 2015). This evidence concerns the gene B2M and ovarian cancer.